Generic placeholder image

Recent Patents on Drug Delivery & Formulation

Editor-in-Chief

ISSN (Print): 1872-2113
ISSN (Online): 2212-4039

Review Article

Nanosuspension Technology: Recent Patents on Drug Delivery and their Characterizations

Author(s): Surya Goel*, Monika Sachdeva and Vijay Agarwal

Volume 13, Issue 2, 2019

Page: [91 - 104] Pages: 14

DOI: 10.2174/1872211313666190614151615

Abstract

Background: Nanosuspension has arisen as a remunerative, lucrative as well as a potent approach to improve the solubility and bioavailability of poorly aqueous soluble drug entities. Several challenges are still present in this approach which need more research. The prime aim of this review is to identify such challenges that can be rectified in the future.

Methods: Through this review, we enlighten the recent patents and advancement in nanosuspension technology that utilize the different drug moieties, instruments and characterization parameters.

Results: Nanosuspension has been found to possess great potential to rectify the several issues related to poor bioavailability, site-specific drug delivery, dosing frequency, etc. In the past decade, nanosuspension approach has been complementarily utilized to solve the developed grievances, arisen from poorly soluble drugs. But this field still needs more attention to new discoveries.

Conclusion: Nanosuspension contributes a crucial role in administering the different drug entities through a variety of routes involving oral, transdermal, ocular, parenteral, pulmonary, etc. with solving the different issues. This review also confirms the significance of nanosuspension in safety, efficacy, and communal as well as the economic expense associated with healthcare.

Keywords: Nanosuspension, drug moieties, bioavailability, solubility, dosing frequency, nanosuspension technology.

Graphical Abstract
[1]
Date AA, Kulkarni RM, Patravale VB. Nanosuspension: A promising drug delivery. J Pharm Pharmacol 2004; 56: 827-40.
[2]
Kreuter J. Colloidal drug delivery systems. In: Kreuter J, Ed. New York: Marcel Dekker, Inc 1994.
[3]
Geetha G, Poojitha U, Khan U. Various techniques for preparation of nanosuspension- A review. Int J Pharm Res Rev 2014; 3: 30-7.
[4]
Muller RH, Peter K. Nanosuspension for the formulation of poorly soluble drugs: Preparation by size reduction technique. Int J Pharm 1998; 160: 229-37.
[5]
Zhang D, Tan T, Gao I, Zhao W, Wang P. Preparation of azithromycin nanosuspension by high-pressure homogenization and its physiochemical characteristics studies. Drug Dev Ind Pharm 2007; 33: 569-75.
[6]
Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon PP, Tozuka Y, Moribe K, Yamamoto K. Formation, physical stability and in-vitro antimalarial activity of dihydroartimisone nanosuspension obtained by the co-grinding method. Drug Dev Ind Pharm 2008; 43: 314-22.
[7]
Moschwitzer J, Achleither G, Pomper H, Muiler RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004; 58: 615-9.
[8]
Xiong R, Lu W, Li J, Wang P, Xu R, Cuen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm 2008; 350: 338-43.
[9]
Van Eerdenbrugh B. Van den MG, Augustijns P. Top down the production of drug nanocrystals- Nanosuspension, miniaturization, and transformation into solid products. Int J Pharm 2008; 364(1): 64-75.
[10]
Krause KP, Kayser O, Mäder K, Gust R, Müller RH. Heavy metal contamination of nanosuspensions produced by high-pressure homogenization. Int J Pharm 2000; 196(2): 169-72.
[11]
Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009; 380: 216-22.
[12]
Li XS, Wang JS, Shen ZG, Zhang PY, Chen JF, Yun J. Preparation of uniform prednisolone microcrystals by a controlled micro- precipitation method. Int J Pharm 2007; 342: 26-32.
[13]
Zhang X, Xia Q, Gu N. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm 2006; 32(7): 857-63.
[14]
Nagaraju P. Nanosuspensions: Promising drug delivery systems. Int J Pharm Sci Nanotech 2010; 2(4): 679-84.
[15]
Prabhakar C, Krishna KB. A review on nanosuspensions in drug delivery. Int J Pharm Biosci 2011; 2(1): 549-58.
[16]
Anjane M, Agrawal S, Khan A. Formulation and evaluation of nanosuspension of valsartan. Int J Curr Pharm Res 2018; 10(2): 68-74.
[17]
Patel HM, Patel UB, Shah C, Akbari B. Formulation and development of nanosuspension as an alternative approach for solubility and dissolution enhancement of aceclofenac. Int J Adv Pharm 2018; 7(5): 33-47.
[18]
Parekh KK, Paun JS, Soniwala MM. Formulation and evaluation of nanosuspension to improve solubility and dissolution of diacerein. Int J Pharm Sci Res 2017; 8(4): 1643-53.
[19]
Upsham VV, Ghate KV, Talware NS. Design and characterization of metformin nanosuspension by nanoprecipitation method. World J Pharm Pharm Sci 2018; 7(9): 738-53.
[20]
Kuppili G, Desu PK, Rao PV. Formulation and evaluation of ezetimibe nanosuspension by using the precipitation method. World J Pharm Pharm Sci 2017; 6(4): 970-9.
[21]
He J, Han Y, Xu G, Yin L, Neubi NM, Zhou Z, et al. Preparation and evaluation of celecoxib nanosuspension for bioavailability enhancement. RSC Adv 2017; 7: 13053-64.
[22]
Md S, Kit CMB, Jagdish S, David JP, Pandey M, Chatterjee LA. Development and in vitro evaluation of a zerumbone loaded nanosuspension drug delivery system. Crystals 2018; 8: 286.
[23]
Raj A. PK A. Development and characterization of bifonazole nitrate nanosuspension loaded topical gel. Res Rev: J Pharm Sci 2018; 9(2): 36-48.
[24]
Pawar RN, Chavan SN, Menon MD. Development, characterization, and evaluation of tinidazole nanosuspension for treatment of amoebiasis. J Nanomed Nanotechnol 2016; 7(6): 1-4.
[25]
Yao J, Cui B, Zhao X, Wang Y, Zeng Z, Sun C, et al. Preparation, characterization and evaluation of azoxystrobin nanosuspension produced by wet media milling. Appl Nanosci 2018; 8(3): 297-307.
[26]
Sumathi R, Tamizharasi S, Sivakumar T. Formulation and evaluation of polymeric nanosuspension of naringenin. Int J App Pharm 2017; 9(6): 60-70.
[27]
Patil AM, Patil IN, Mane RU, Randive DS, Bhutkar MA, Bhinge SD. Formulation optimization and evaluation of cefdinir nanosuspension using factorial design. Marmara Pharm J 2018; 22(4): 587-98.
[28]
Sumathi R, Tamizharasi S, Gopinath K, Sivakumar T. Formulation, characterization and in vitro release study of silymarin nanosuspension. Indo Am J Pharm Sci 2017; 4(1): 85-94.
[29]
Kumar P, Chandrasekhar KB. Formulation and in-vitro and in-vivo characterization of nifedipine stabilized nanosuspension by nanoprecipitation method. Int J Res Pharm Sci 2017; 8(4): 759-66.
[30]
Qureshia MJ, Phina FF, Patrob S. Enhanced solubility and dissolution rate of clopidogrel by nanosuspension: Formulation via high-pressure homogenization technique and optimization using box Behnken design response surface methodology. J Appl Pharm Sci 2017; 7(2): 106-13.
[31]
Dzakwan M, Pramukantoro GE, Mauludin R, Wikarsa S. Formulation and characterization of fisetin nanosuspension. IOP Conf Ser Mater Sci Eng 2017 259. 1-5.
[32]
Hemalatha K, Rajashekar S. Formulation and evaluation of rosiglitazone nanosuspension. Intercon J Pharma Inv Res 2017; 4(1): 29-43.
[33]
Dawood NM, Abdul-Hammid SN, Hussein AA. Formulation and characterization of lafutidine nanosuspension for oral drug delivery system. Int J App Pharm 2018; 10(2): 20-30.
[34]
Li Q, Chen F, Liu Y, Yu S, Gai X, Ye M, et al. A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. Int J Nanomed 2018; 13: 4711-25.
[35]
Bommagani M, Bhowmick SB, Kane P, Dubey V. Method of preparing the nanoparticulate topical composition. WO2016135753Al (2016).
[36]
Mao S, Guan J, Helgerud T, Zhang Y. Nanosuspension formulation. WO2016081593Al 2016.
[37]
Inghelbrecht SKK, Beirowski JA, Gieseler H. Freeze dried drug nanosuspension. US20160317534A1 2016.
[38]
Gerusz V, Mouze C, Van F, Ameye D. Novel drug formulation. US20160206577A1 (2016).
[39]
Kablitz C. New treatment of fish with a nanosuspension of lufenuron or hexaflumuron. US20150238446A1 (2015).
[40]
Xu S, Zhu Y, Fan Q, Ou S, Liu X. Nanosuspension of tobramycin and dexamethasone and preparation method thereof. CN105708844 2016.
[41]
Shi S. Method of preparation of nanocrystals of simvastatin 2016. CN105315249 (2016).
[42]
Zhang L, Wu S, Li Z, et al. Method of developing celecoxib nanosuspension capsule. CN105534947 (2016).
[43]
Zhang J. Lurasidone and its preparation method thereof. CN104814926 (2015).
[44]
Chen MJ. Nanosuspension of poor water soluble drug via microfludization process. US20152655344A1 (2015).
[45]
Thodeti S, Reddy RM, Kumar JS. Synthesis and characterization of pure and indium doped SnO2 nanoparticles by sol-gel methods. Int J Sci Eng Res 2016; 7: 310-7.
[46]
Thodeti S, Bantikatla HB, Kumar YK, Sathish B. Synthesis and characterization of ZnO nanostructures by oxidation technique. Int J Adv Res Sci Engr 2017; 6: 539-44.
[47]
Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. J Appl Pharm Sci 2011; 1: 228-34.
[48]
Gupta AL, Kumar M. Group theory and spectroscopy. 1st ed. Pragati Prakashan India 2013.
[49]
Mourdikoudis S, Pallares RM, Thanh N. Characterization techniques for nanoparticles: Comparison and complementary upon studying nanoparticles properties. Nanoscale 2018; 10: 12871-934.
[50]
Pangi Z, Beletsi A, Evangelatos K. PEG-ylated nanoparticles for biological and pharmaceutical application. Adv Drug Del Res 2003; 24: 403-19.
[51]
Tyndall J. On the blue color of the sky, the polarization of skylight, and the polarization of light by cloudy matter generally. Proc Royal Soc Lond 1868; 17: 223-33.
[52]
Stetefeld J, Mckenna SA, Patel TR. Dynamic light scattering: A practical guide and applications in biomedical sciences. Biophys Rev 2016; 8: 409-27.
[53]
Kodre KV, Attarde SR, Yendhe PR, Patil RY, Barge VU. Differential scanning calorimetry: A review. Res Rev J Pharm Analysis 2014; 3(3): 11-22.
[54]
Skoog DA, Holler FJ, Crouch SR. Thermal Methods. Instrumental Analysis. India edition: Cengage Learning, 2011: 982-84.
[55]
Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental methods of analysis. 7th ed. CBS publishers 2012.
[56]
Muhlen AZ, Muhlen EZ, Niehus H, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 1996; 13: 1411-6.
[57]
Shi HG, Farber L, Michaels JN, Dickey A, Thompson KC, Shelukar SD, et al. Characterization of crystalline drug nanoparticles using atomic force microscopy and complementary techniques. Pharm Res 2003; 20: 479-84.
[58]
Berthomieu C, Hienerwadel R. Fourier transform infrared (FTIR) spectroscopy. Photosynth Res 2009; 101: 157-70.
[59]
Margarita P, Quinteiro R. Fourier transform infrared (FT-IR) technology for the identification of organisms. Clinical Microbiol Newsl 2000; 22(8): 57-61.
[60]
Maquelin K, Kirschner C. Identification of medically relevant microorganisms by vibrational spectroscopy. J Microbiol Meth 2002; 51: 255-71.
[61]
Lipkus AH, Chittur KK, Vesper SJ. Evolution of infrared spectroscopy as a bacterial identification method. J Ind Microbiol 1990; 6: 71-5.
[62]
Curk MC, Peledan F, Hubert JC. Fourier transforms infrared (FT-IR) spectroscopy for identifying Lactobacillus species. FEMS Microbiol Lett 1994; 123: 241-8.
[63]
Siebert F. Infrared spectroscopy applied to biochemical and biological problems. Methods Enzymol 1995; 246: 501-26.
[64]
Jackson M, Sowa MG. Infrared spectroscopy: A new frontier in medicine. Biophys Chem 1997; 68: 109-25.
[65]
Diem M, White B. Infrared spectroscopy of cells and tissues: Shining light onto a novel subject. Appl Spectrosc 1999; 53: 148-61.
[66]
Wenning M, Seiler H, Scherer S. Fourier-transform infrared microspectroscopy, a novel and rapid tool for identification of yeast. Appl Environ Microbiol 2002; 68(10): 4717-21.
[67]
Khursheed A. Scanning electron microscope. US7294834B2 (2007).
[68]
Boughorbel F, Kooijman CS, Lich BH, Bosch EG. SEM imaging method. US8232523B2 2012.
[69]
Bierhoff MP, Buijsse B, Kooijman CS, et al. Compact scanning electron microscope. US20100230590 (2010).
[70]
Gendreau K, Martins JV, Arzoumanian Z. Instrument and method for X-ray diffraction, fluorescence, and crystal texture analysis without sample preparation. US7796726B1 (2010).
[71]
Blake DF, Bryson C, Freund F. X-ray diffraction method. US5491738 (1996).
[72]
Cernik R. Tomographic energy dispersive X-ray diffraction apparatus comprising an array of detectors of associated collimators. US7564947B2 (2009).
[73]
Shibata N, Inami W, Sawada H. Transmission electron microscope. US8431897B2 (2013).
[74]
Jonge ND. Transmission electron microscopy for imaging live cells. US20120120226 (2012).
[75]
O'Brien RW. Determination of particle size and electrical charge. US5059909 (1991).
[76]
Danley RL. Quasiadiabatic differential scanning calorimeter. WO2014039376A3 (2014).
[77]
Danley RL. Modulated differential scanning calorimeter and its method thereof. US6561692B2 (2003).
[78]
Williams J, Owens M. Micro-electromechanical system based thermo-gravimetric analysis instrument and its method thereof. US20040141541 (2004).
[79]
Huetter T, Joerimann U, Wiedemann HG. Differential analysis system including dynamic mechanic analysis and its method thereof. US6146013 (2000).
[80]
Reed KJ, Levchak MJ, Schaefer JW. Thermogravimetric apparatus and its method thereof. US5321719 (1994).
[81]
Blumberg G, Schlockermann CJ. Atomic force microscope and its operating method thereof. US7111504B2 (2006).
[82]
Hough PVC, Wang C. Sensing mode atomic force microscope. US6818891B1 (2004).
[83]
Sivasankar S, Li H. System, apparatus, and method for simultaneous single-molecule atomic force microscopy and fluorescence measurements. US8656510B1 (2014).
[84]
Hu Y, Hu S, Su C. Method and apparatus of operating a scanning probe microscope. US8739309B2 (2014).
[85]
Levin KH, Kerem S, Madorsky V. Handheld infrared spectrometer. US6031233 (2000).
[86]
Rapp N, Simon A. Digital FTIR spectrometer. US7034944B2 (2006).
[87]
Simon A. Imaging FTIR spectrometer. US20030103209 (2003).
[88]
Will N, Hielscher B, Becker C, Andres B, Rathke C. Method for operating an FTIR spectrometer, and FTIR spectrometer. US20100282958A1 (2010).
[89]
Huikai X, Lei W, Andrea P, Robert SS. MEMS-based FTIR spectrometer. WO2010096081 (2010).
[90]
Haught RC, Klinkhammer GP, Bussell FJ. Zero angle photon spectrophotometer for monitoring of water system. US8102518B2 (2012).
[91]
Watson FM. Continuous particle and macro-molecular zeta potential measurements using field flow fractionation combined microelectrophoresis. US8573404B2 (2013).
[92]
Bright C. Wellbore FTIR gas detection system. US9217810B2 (2015).
[93]
Pringle AT. Ultraviolet disinfection device and its method. WO2015116876Al (2015).
[94]
Lacey A, Reading M. Differential scanning calorimeter. US6641300B1 (2003).
[95]
Menard KP, Diz EL, Spragg R. DSC-RAMEN analytical system and its method. US2011/0170095 (2011).
[96]
Agarwal V, Bajpai M. Stability issues related to nanosuspension: A review. Pharm Nanotech 2013; 1: 85-92.
[97]
Keck CM, Mullar RH. Drug nanocrystals of poorly soluble drugs produced by high-pressure homogenization. Eur J Pharm Biopharm 2006; 62: 3-16.
[98]
Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004; 284: 109-22.
[99]
Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine 2006; 1(2): 157-68.
[100]
Junghanns JUAH, Muller RH. Nanocrystal technology, drug delivery, and clinical applications. Int J Nanomed 2008; 3(3): 295-309.
[101]
Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): Products on the market. Int J Nanomed 2014; 9: 4357-73.
[102]
Mansour HM, Park CW, Bawa R. Design and development of approved nanopharma-ceutical products. Handbook of Clinical Nanomedicine -From Bench to Bedside. In: Bawa R, Audette GF, Rubinstein I, Eds. Singapore: Pan Stanford Publishing Ltd 2015; pp. 1-33.
[103]
Marcato PD, Duran N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008; 8(5): 1-14.
[104]
Agarwal V, Bajpai M, Sharma A. Patented and approval scenario of nanopharmaceuticals with relevancy to biomedical application, manufacturing procedures and safety aspects. Rec Patents Drug Deliv Formula 2018; 12(1): 40-52.
[105]
Tinkle S, McNeil SE, Muhlebach S, Bawa R, Borchard G, Barenholz Y, et al. Nanomedicines: Addressing the scientific and regulatory gap. Ann N Y Acad Sci 2014; 1313: 35-56.

© 2024 Bentham Science Publishers | Privacy Policy